9～14岁女性人乳头瘤病毒疫苗接种现状及其影响因素分析

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (650 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解9～14岁女性接种人乳头瘤病毒疫苗的现状及其影响因素,为更好地推广国内HPV疫苗接种提供建议。方法 2019年6月—12月调查山西白求恩医院妇产科门诊就诊的育有9～14岁女童的母亲,使用自填式调查问卷,内容包括一般资料、疫苗接种情况及其对HPV疫苗认知度为其女接种疫苗的意愿。结果 322名调查对象中,9～14岁女童的疫苗接种率为1.9％。63.0％的母亲了解HPV疫苗可以预防宫颈癌,36.7％了解青春期女性接种HPV疫苗可获得较高的免疫效果。64.59％表示愿意为其女接种HPV疫苗。单因素分析结果显示,监护人年龄、职业类型、家庭年收入、本人是否已接种疫苗、对HPV疫苗的认知度及接种意愿均影响9～14岁女童的疫苗接种率。多因素Logistic回归分析结果显示,监护人对HPV疫苗的认知度、接种意愿及家庭年收入影响9～14岁女童的HPV疫苗接种率。结论太原市某地区9～14岁女童的母亲为其女接种HPV疫苗的意愿较高,但实际接种率不理想。应针对特定人群进行宣传教育,提高认知度,同时针对该年龄段女性制定免疫接种计划,提高9～14岁女性HPV疫苗接种率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邱丽蓉
	牛战琴

关键词 ： 9～14岁女性, 人乳头瘤病毒疫苗, 接种现状, 影响因素

收稿日期: 2020-09-21

ZTFLH:

R17

通讯作者: 牛战琴(niuzhanqin@126.com)

引用本文:

邱丽蓉, 牛战琴. 9～14岁女性人乳头瘤病毒疫苗接种现状及其影响因素分析[J]. 中国生育健康杂志, 2022, 33(3): 262-265.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2022/V33/I3/262

1 刘萍.中国大陆13年宫颈癌临床流行病学大数据评价.中国实用妇科与产科杂志,2018,34:41-45.
2 胡尚英,乔友林.2017年WHO HPV疫苗立场文件的解读.中华预防医学杂志,2018,52:464-468.
3 Workowski KA,Bolan GA;Center for Disease Control and Prevention sexually transmitted diseases treatment guidelines,2015. MMWR Recomm Rep,2015,64:1-137.
4 Human papillomavirus vaccines:WHO position paper,2017. Wkly Epidemiol Rec,2017,92:241-268.
5 Saslow D,Andrews KS,Manassaram-Baptiste D,et al.American Cancer Society Guideline Development Group.Human papillomavirus vaccination 2020 guideline update:American Cancer Society guideline adaptation.CA Cancer J Clin.2020,70:274-280.
6 Li KM,Li QL,Song L et al.The distribution and prevalence of human papillomavirus in women in mainland China.Cancer,2019,125:1030-1037.
7 Luo Q,Jiang N,Wu QY et al.Prevalence and genotype distribution of HPV and cervical pathological results in Sichuan Province,China:a three years surveys prior to mass HPV vaccination .Virol J,2020,17:100.
8 赵春艳,石晶,张国峰,孙远洁,邓艳春,张建明.北京市通州区中小学女生母亲接受女儿接种HPV疫苗情况及其影响因素.中国学校卫生,2020,41:597-600.
9 Department of Health and Human Services.IID-11.4.Increase the percentage of female adolescent aged 13 through 15 years who receive 2 or 3 doses of human papiuomavirus (HPV) vaccine as recommend [EB/OL].[2018-09-22] .https://www.Healthypeople.gov/2020/topics-objectives/topic /immunization-and-infectious-diseases/objectives.
10 卢晓燕.女性HPV感染情况及对HPV和HPV疫苗的认知情况调查.中国妇幼保健,2020,35:526-529.
11 吴婵,周怀君,李梅.关于美国妇产科医师协会\"HPV疫苗接种的委员会意见\"的解读.中华妇产科杂志,2017:354-357.
12 Committee Opinion No.704:Human Papillomavirus Vaccination.Obstet Gynecol,2017,52:,129:e173-e178.
13 Olsson SE,Restrepo JA,Reina JC,et al.Long-term immunogenicity,effectiveness,and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age:Interim analysis after 8 years of follow-up.Papillomavirus Res.2020,10:100203.
14 Rotstein Grein IH,Pinto NF,Lobo A,et al.Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus:a real-world interventional multi-centre study.Lupus.2020,29:934-942.
15 Chen W,Zhao Y,Xie X et al.Safety of a quadrivalent human papillomavirus vaccine in a Phase 3,randomized,double-blind,placebo-controlled clinical trial among Chinese women during 90 months of follow-up.Vaccine,2019,37:889-897.
16 Arbyn M,Xu L,Efficacy and safety of prophylactic HPV vaccines.A Cochrane review of randomized trials.Expert Rev Vaccines,2018,17:1085-1091.